FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours ner response:								

	tion 1(b).	iue. See		Filed	pursua or Se	ant to S ection 3	Section 1 30(h) of t	.6(a) the In	of the	e Secu ment C	urities Compa	Exchan	ge Act of 1940	of 1934			hours	per re	sponse:	0.5
1. Name and Address of Reporting Person* GRAHAM RICHARD A					2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]									all app	tor	ıg Per	10% Ov	vner		
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD				3. Date of Earliest Transaction (Month/Day/Year) 12/14/2020									X Officer (give title below) Other (specify below) SVP, Development					вреспу 		
(Street) SOUTH FRANCE	ISCO CA		408 Zip)	0	4. If Amendment, Date of Original Filed (Month/Day/Year)							Indivine)	,							
	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				2A. Deemed Execution Date,		3. Tra	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			d (A) or	5. A Sec Ben Owi		ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership		
						C		Code V		Amount ((A) or (D)	Price			ted action(s) 3 and 4)	(Instr. 4)		(Instr. 4)	
Ordinary	Ordinary Shares 12/14/202		12/14/202	0				s		7,5	500	D	\$19.474	14 ⁽¹⁾	123,749			D		
		Tal	ble	II - Derivati (e.g., pu												wne	d			
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transa Code (action	5. Num of Derivat Securit Acquire (A) or Dispos of (D)	5. Number of Derivative Securities Acquired A) or Disposed of (D) Instr. 3, 4			ercisal Date	ble and	7. Tit Amo Secu Unde	le and unt of rities rlying ative rity (Instr.	8. Pi Deri Sec	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
														or Number						

Explanation of Responses:

1. This transaction was executed in multiple trades at prices from \$19.46 to \$19.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

(D)

Date

Exercisable

Brett A. Grimaud, Attorney-

Shares

in-Fact

Expiration Date

** Signature of Reporting Person Date

12/16/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.